melanoma

melanoma

melanoma

Pharmaceutical companies Moderna and Merck have announced preliminary successes in the Phase 3 trial of their personalised melanoma vaccine

In a press release, the pharmaceutical companies Moderna and Merck have announced the results of their ongoing Phase 3 INTerpath-001 clinical trial, which is evaluating an mRNA vaccine (intismeran) in combination with pembrolizumab in patients with completely resected Stage IIB–IV melanoma. There is as yet no scientific publication containing data on improved survival or a reduction in recurrence.

0

Cases of skin cancer in people over the age of 65 will increase in the coming decades

Research analyzing data from more than 200 countries concludes that people over the age of 65 will face an increase in skin cancer cases over the next two decades. The study, published in JAMA Dermatology, used data from 1990 to 2021 and made estimates through 2050. Men and people living in countries with higher sociodemographic indices showed a higher incidence.

0